Literature DB >> 10412734

Lipoprotein glomerulopathy: significance of lipoprotein and ultrastructural features.

T Saito1, S Oikawa, H Sato, T Sato, S Ito, J Sasaki.   

Abstract

BACKGROUND: Lipoprotein glomerulopathy (LPG) is a unique disease characterized by intraglomerular lipoprotein thrombi and type III hyperlipoproteinemia. Recently, we have demonstrated that LPG is associated with inherited apolipoprotein E (apoE) variants including apoE Sendai. On the other hand electron microscopy shows that intraglomerular lipoprotein thrombi consist of lipid granules of various sizes. To elucidate the relationship between the peculiar histology and abnormal lipid metabolism related to apoE Sendai, we studied lipoprotein profiles and ultrastructural features.
METHODS: The subjects were 11 patients with LPG. Four patients were nephrotic, and two others became nephrotic within six months following the biopsy. Eight patients underwent apoE gene analysis and showed apoE Sendai. The other three were presumed to have apoE Sendai because this mutation was demonstrated in their kindreds. Under electron microscopy, diameters of more than 1000 lipid granules were measured in several glomeruli, and a mean value was calculated in each case. Lipoprotein profiles were analyzed by the ultracentrifugation methods.
RESULTS: The mean diameter of intraglomerular lipid granules correlated inversely with the levels of plasma triglyceride (TG; rs = -0.73, P < 0.05), TG (rs = -0.77, P < 0.01) and cholesterol (Chol; rs = -0.75, P < 0.05) in very low-density lipoprotein (VLDL) fraction and TG in high-density lipoprotein (HDL) fraction (rs = -0.75, P < 0.05). The inverse correlation was also seen between the mean lipid diameter and TG/Chol ratios in whole plasma (rs = -0.80, P < 0.01) and in HDL (rs = -0.80, P < 0.01). In addition, the cases showing smaller lipid granules and higher TG/Chol ratios in plasma and in HDL were nephrotic or became nephrotic within six months.
CONCLUSION: These results suggest that the size of lipid granules in LPG may become smaller under the influence of hypertriglyceridemia and particularly elevated plasma VLDL and HDL-TG, which may lead to heavy proteinuria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10412734     DOI: 10.1046/j.1523-1755.1999.07110.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  9 in total

1.  Dysbetalipoproteinemia: Two cases report and a diagnostic algorithm.

Authors:  Anastazia Kei; George Miltiadous; Eleni Bairaktari; Marilena Hadjivassiliou; Marios Cariolou; Moses Elisaf
Journal:  World J Clin Cases       Date:  2015-04-16       Impact factor: 1.337

2.  Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.

Authors:  Hagai Tavori; Daping Fan; Ilaria Giunzioni; Lin Zhu; MacRae F Linton; Agnes B Fogo; Sergio Fazio
Journal:  J Lipid Res       Date:  2014-09-02       Impact factor: 5.922

3.  Lipoprotein Glomerulopathy, First Case Report from Canada.

Authors:  Julie Anne Ting; Susanna A McRae; Daniel Schwartz; Sean J Barbour; Maziar Riazy
Journal:  Int J Nephrol Renovasc Dis       Date:  2022-06-21

Review 4.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

5.  Lipoprotein glomerulopathy induced by ApoE-Sendai is different from glomerular lesions in aged apoE-deficient mice.

Authors:  Atsunori Ishimura; Maho Watanabe; Hitoshi Nakashima; Kenji Ito; Katsuhisa Miyake; Shizue Mochizuki; Yasushi Ishigaki; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2009-05-21       Impact factor: 2.801

Review 6.  Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity.

Authors:  Miho Karube; Kimimasa Nakabayashi; Yasunori Fujioka; Ken Yoshihara; Akira Yamada; Akira Matsunaga; Takao Saito
Journal:  Clin Exp Nephrol       Date:  2007-06-28       Impact factor: 2.801

7.  Identification of apolipoprotein E Guangzhou (arginine 150 proline), a new variant associated with lipoprotein glomerulopathy.

Authors:  Boxun Luo; Fengxian Huang; Qicai Liu; Xiaoyan Li; Wenfang Chen; Shu-Feng Zhou; Xueqing Yu
Journal:  Am J Nephrol       Date:  2007-11-29       Impact factor: 3.754

8.  A case of nephrotic syndrome showing contemporary presence of apolipoprotein E2 homozygote glomerulopathy and membranous nephropathy-like findings modified by apolipoprotein E Toyonaka.

Authors:  Hisako Hirashima; Toshiyuki Komiya; Naoya Toriu; Shigeo Hara; Akira Matsunaga; Takao Saito; Eri Muso
Journal:  Clin Nephrol Case Stud       Date:  2018-11-30

9.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka (Ser197Cys) and a Homozygous Apolipoprotein E2/2.

Authors:  Megumu Fukunaga; Kiyotaka Nagahama; Michiko Aoki; Akira Shimizu; Shigeo Hara; Akira Matsunaga; Eri Muso; Takao Saito
Journal:  Case Rep Nephrol Dial       Date:  2018-03-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.